The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC

被引：0
|
作者：
Sarina, Piha-Paul
Xu, Binghe
Fan, Ying
Yuan, Yuan
Lavasani, Sayeh
Mortimer, Joanne
Goel, Sanjay
Tsimberidou, Apostolia
Ibrahim, Nuhad
Abouharb, Sausan
Barcenas, Carlos
Lheme, Adaeze
Karp, Daniel
Ahnert, Jordi Rodon
Dumbrava, Ecaterina
Fan, Jean
Peng, Peng
Sun, Caixia
Wang, Hui
Hennessy, Katie
Fu, Ximei
Xu, Ruolan
Ni, Shumao
Wu, Frank
Meric-Bernstam, Funda
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-RF01-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
RF01-07
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2-Breast Cancer
    Kang, Connie
    TARGETED ONCOLOGY, 2024, 19 (02) : 289 - 296
  • [2] Breast Cancer CDK4/6 Inhibitors in Patients with metastatic HR+/HER2-Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [3] Ribociclib in HR+/HER2-Advanced or Metastatic Breast Cancer Patients
    Rascon, Kaitlin
    Flajc, Goran
    De Angelis, Carmine
    Liu, Xinli
    Trivedi, Meghana V.
    Ekinci, Ekim
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 501 - 509
  • [4] TREATMENT PATTERNS AND PROGNOSTIC FACTORS OF LOCALLY ADVANCED OR METASTATIC HR+ / HER2-BREAST CANCER IN ARGENTINA
    Novick, D.
    Moneta, M., V
    Fischman, M.
    Zarino, N.
    Gallino, J.
    Carter, Cuyun G.
    Haro, J. M.
    VALUE IN HEALTH, 2020, 23 : S62 - S63
  • [5] Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
    Ban, Marija
    Mise, Branka Petric
    Majic, Ana
    Drazic, Ivanka
    Vrdoljak, Eduard
    FUTURE ONCOLOGY, 2018, 14 (06) : 537 - 544
  • [6] Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2-Advanced or Metastatic Breast Cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Fatima, Eeshal
    Altaf, Faryal
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (01): : 6 - 15
  • [7] Everolimus and Exemestane An Innovative Therapeutic Option for Patients with advanced HR+, HER2-Breast Cancer
    Grischke, Eva-Maria
    Geberth, Matthias
    Harbeck, Nadia
    AKTUELLE NEUROLOGIE, 2014, 41 (08) : 4 - 6
  • [8] SG Improves OS in HR+/HER2-Breast Cancer
    Poh, Alissa
    CANCER DISCOVERY, 2022, 12 (12) : 2714 - 2715
  • [9] Comprehensive genomic profiling of advanced HR+/HER2-breast cancer patients using liquid biopsy
    Shao, B.
    Tang, H.
    Liu, X-R.
    Song, G.
    Di, L.
    Xie, F.
    Jia, C.
    Zhang, Y.
    Jia, S.
    Li, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S389 - S389
  • [10] Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2-Breast Cancer
    Chang, Jenny C.
    O'Regan, Ruth
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 : S1 - S14
12345